---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-027323"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2021-11-23T23:59:59+00:00"
generated_at: "2026-06-28T05:44:13.084270+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# AcelRx appoints Jill Broadfoot as Class I director; board size set to ten

## Summary
- Jill Broadfoot appointed to AcelRx board effective Nov 20, 2021; serves on Audit Committee.
- Board size fixed at ten directors (4 Class I, 3 Class II, 3 Class III).
- Broadfoot receives option for 30,000 shares at $0.7192 and 15,000 RSUs per director compensation policy.
- Broadfoot is CFO of aTyr Pharma and formerly CFO of Vical, with audit and finance background.

## SEC filing metadata
- accession: 0001437749-21-027323
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2021-11-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774921027323/0001437749-21-027323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774921027323/acrx20211123_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-027323
- JSON: https://secwatch.observer/filing/0001437749-21-027323.json
- Plain text: https://secwatch.observer/filing/0001437749-21-027323.txt

## Key facts
- Executive change
  Jill M. Broadfoot was appointed as Class I Director at TALPHERA, INC..
  - Action: appointed
  - Role: Class I Director
  source text: On November 20, 2021, the Board of Directors (the “Board”) of AcelRx Pharmaceuticals, Inc. (the “Company”) appointed Jill M. Broadfoot a Class I director of the Board, effective November 20, 2021, to serve until the expiration of her term at the 2024 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427925/000143774921027323/0001437749-21-027323-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.